105 related articles for article (PubMed ID: 2709378)
1. Dynamics and thermodynamics of the counterion effect in a 7H-pyridocarbazole dimer (ditercalinium). Hypothesis of a nonbisintercalative binding mode to calf thymus DNA at high drug/base ratio.
Dodin G
J Med Chem; 1989 May; 32(5):1127-34. PubMed ID: 2709378
[TBL] [Abstract][Full Text] [Related]
2. Ditercalinium, a nucleic acid binder, inhibits the respiratory chain of isolated mammalian mitochondria.
Dupont J; Schwaller MA; Dodin G
Cancer Res; 1990 Dec; 50(24):7966-72. PubMed ID: 2174739
[TBL] [Abstract][Full Text] [Related]
3. Tight binding of the antitumor drug ditercalinium to quadruplex DNA.
Carrasco C; Rosu F; Gabelica V; Houssier C; De Pauw E; Garbay-Jaureguiberry C; Roques B; Wilson WD; Chaires JB; Waring MJ; Bailly C
Chembiochem; 2002 Dec; 3(12):1235-41. PubMed ID: 12465032
[TBL] [Abstract][Full Text] [Related]
4. Geometry of the antitumor drug ditercalinium bisintercalated into d(CpGpCpG)2 by 1H NMR.
Delbarre A; Delepierre M; Garbay C; Igolen J; Le Pecq JB; Roques BP
Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2155-9. PubMed ID: 3470783
[TBL] [Abstract][Full Text] [Related]
5. The noncovalent complex between DNA and the bifunctional intercalator ditercalinium is a substrate for the UvrABC endonuclease of Escherichia coli.
Lambert B; Jones BK; Roques BP; Le Pecq JB; Yeung AT
Proc Natl Acad Sci U S A; 1989 Sep; 86(17):6557-61. PubMed ID: 2671994
[TBL] [Abstract][Full Text] [Related]
6. Recognition by the DNA repair system of DNA structural alterations induced by reversible drug-DNA interactions.
Lambert B; Segal-Bendirdjian E; Esnault C; Le Pecq JB; Roques BP; Jones B; Yeung AT
Anticancer Drug Des; 1990 Feb; 5(1):43-53. PubMed ID: 2180423
[TBL] [Abstract][Full Text] [Related]
7. Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II.
Markovits J; Pommier Y; Mattern MR; Esnault C; Roques BP; Le Pecq JB; Kohn KW
Cancer Res; 1986 Nov; 46(11):5821-6. PubMed ID: 3019538
[TBL] [Abstract][Full Text] [Related]
8. Cytokinetic effects of bifunctional antitumor intercalator ditercalinium on Friend erythroleukemia cells.
Traganos F; Bueti C; Melamed MR; Darzynkiewicz Z
Leukemia; 1987 May; 1(5):411-6. PubMed ID: 3478539
[TBL] [Abstract][Full Text] [Related]
9. DNA sequence recognition by the antitumor drug ditercalinium.
Crow SD; Bailly C; Garbay-Jaureguiberry C; Roques B; Shaw BR; Waring MJ
Biochemistry; 2002 Jul; 41(27):8672-82. PubMed ID: 12093285
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the size and position of substituents on 7H-pyrido[4,3-c]carbazole monomers and dimers and their DNA binding and anti-tumor properties.
Léon P; Garbay-Jaureguiberry C; Le Pecq JB; Roques BP
Anticancer Drug Des; 1988 Jun; 3(1):1-13. PubMed ID: 3382504
[TBL] [Abstract][Full Text] [Related]
11. Intercalative binding of ditercalinium to d(CpGpCpG)2: a theoretical study.
Maroun R; Delepierre M; Roques BP
J Biomol Struct Dyn; 1989 Dec; 7(3):607-21. PubMed ID: 2627301
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics simulations of the bis-intercalated complexes of ditercalinium and Flexi-Di with the hexanucleotide d(GCGCGC)2: theoretical analysis of the interaction and rationale for the sequence binding specificity.
de Pascual-Teresa B; Gallego J; Ortiz AR; Gago F
J Med Chem; 1996 Nov; 39(24):4810-24. PubMed ID: 8941395
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the bis-intercalating complexes formed between either ditercalinium or a flexible analogue and d(CpGpCpG)2 or d(TpTpCpGpCpGpApA)2 minihelices: 1H- and 31P-NMR analyses.
Pothier J; Delepierre M; Barsi MC; Garbay-Jaureguiberry C; Igolen J; Le Bret M; Roques BP
Biopolymers; 1991 Oct; 31(11):1309-23. PubMed ID: 1777582
[TBL] [Abstract][Full Text] [Related]
14. The antitumor intercalating drug ditercalinium binds preferentially to RNA in Friend erythroleukemia cells.
Traganos F; Bueti C; Kapuscinski J; Darzynkiewicz Z
Leukemia; 1989 Jul; 3(7):522-9. PubMed ID: 2471903
[TBL] [Abstract][Full Text] [Related]
15. Interactions of antitumor drug ditercalinium with nucleic acids in solutions and in situ.
Kapuscinski J; Traganos F; Darzynkiewicz Z
Cancer Lett; 1988 Nov; 42(3):185-91. PubMed ID: 3191470
[TBL] [Abstract][Full Text] [Related]
16. 1H- and 31P-NMR studies of ditercalinium binding to a d(GCGC)2 and d(CCTATAGG)2 minihelices: a sequence specificity study.
Delepierre M; Milhe C; Namane A; Dinh TH; Roques BP
Biopolymers; 1991 Feb; 31(3):331-53. PubMed ID: 1868161
[TBL] [Abstract][Full Text] [Related]
17. DNA distortion in bis-intercalated complexes.
Peek ME; Lipscomb LA; Bertrand JA; Gao Q; Roques BP; Garbay-Jaureguiberry C; Williams LD
Biochemistry; 1994 Apr; 33(13):3794-800. PubMed ID: 8142381
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic accumulation of ditercalinium in rat hepatocytes and induction of mitochondrial damage.
Fellous R; Coulaud D; el Abed I; Roques BP; Le Pecq JB; Delain E; Gouyette A
Cancer Res; 1988 Nov; 48(22):6542-9. PubMed ID: 3180068
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of new dimers in the 7H-pyrido[4,3-c] carbazole antitumor series.
Garbay-Jaureguiberry C; Barsi MC; Jacquemin-Sablon A; Le Pecq JB; Roques BP
J Med Chem; 1992 Jan; 35(1):72-81. PubMed ID: 1732535
[TBL] [Abstract][Full Text] [Related]
20. Selective alteration of mitochondrial function by Ditercalinium (NSC 335153), a DNA bisintercalating agent.
Esnault C; Brown SC; Segal-Bendirdjian E; Coulaud D; Mishal Z; Roques BP; Le Pecq JB
Biochem Pharmacol; 1990 Jan; 39(1):109-22. PubMed ID: 2297352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
